Novartis COPD Drug Wil Test The LABA Safety Waters During Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Given the known risks of long-acting beta-2 agonists, a safety discussion seems likely when the Pulmonary-Allergy Drugs Advisory Committee meets to review Novartis' Arcapta Neohaler (indacaterol maleate).
You may also be interested in...
Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva
The once-daily COPD treatment, already approved in Europe with ho-hum sales, is a lynchpin of Novartis' plan to establish a respiratory franchise.
LABA Safety Studies, REMS Are Next Topics For Sponsors, FDA After Relabeling
Discussions about how best to study the safety of long-acting beta agonists are ready to resume now that FDA has issued a revised label for the drug class
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting